نتایج جستجو برای: cd52

تعداد نتایج: 350  

2016
Ryuichi Hotta Masahiro Ohira Toshiharu Matsuura Izumi Muraoka Panagiotis Tryphonopoulos Ji Fan Akin Tekin Gennaro Selvaggi David Levi Phillip Ruiz Camillo Ricordi Rodrigo Vianna Hideki Ohdan Herman Waldmann Andreas G. Tzakis Seigo Nishida

BACKGROUND T-cell depleting strategies have become an integral part of immunosuppressive regimens in organ transplantation. Alemtuzumab is a humanized monoclonal antibody against CD52, a cell-surface antigen on several immune cells. It has been suggested that lymphocyte depletion increases the risk of serious infections. However, this has not been observed with short-term alemtuzumab treatment ...

Journal: :The British journal of nutrition 2014
Honggang Wang Jianning Dong Lugen Zuo Jianhui Liu Weiming Zhu Yi Li Lili Gu Jie Zhao Liang Zhang Jianfeng Gong Wei Zhang Ning Li Jieshou Li

Approximately 50 % of patients with inflammatory bowel disease (IBD) suffer from anaemia, with Fe deficiency being the most common cause. CD52 monoclonal antibody (mAb) targets the cell surface CD52 and is effective in depleting lymphocytes through cytolytic effects in vivo. The aim of the present study was to investigate the therapeutic effect of anti-mouse CD52 mAb on Fe-deficient anaemia in ...

Journal: :Blood 1995
B Hertenstein B Wagner D Bunjes C Duncker A Raghavachar R Arnold H Heimpel H Schrezenmeier

CD52 is a phosphatidylinositolglycan (PIG)-anchored glycoprotein (PIG-AP) expressed on normal T and B lymphocytes, monocytes, and the majority of B-cell non-Hodgkin lymphomas. We observed the emergence of CD52- T cells in 3 patients after intravenous treatment with the humanized anti-CD52 monoclonal antibody Campath-1H for refractory B-cell lymphoma and could identify the underlaying mechanism....

Journal: :International immunology 2000
R A Hederer C Guntermann N Miller P Nagy J Szollosi S Damjanovich G Hale D R Alexander

Campath-1H, a humanized mAb undergoing clinical trials for treatment of leukemia, transplantation and autoimmune diseases, produces substantial lymphocyte depletion in vivo. The antibody binds to CD52, a highly glycosylated molecule attached to the membrane by a glycosylphosphatidylinositol anchor. Cross-linked Campath-1H is known to activate T cells in vitro. We have investigated the molecular...

Journal: :The Biochemical journal 1997
V C Taylor M Sims S Brett M C Field

The CD52 antigen is a lymphocyte glycoprotein with an extremely short polypeptide backbone and a single N-linked glycan, and it is attached to the cell membrane by a glycosylphosphatidylinositol (GPI) anchor. Treatment of rheumatoid arthritis patients with CAMPATH-1H, a humanized monoclonal antibody against CD52, resulted, in a small number of cases, in the appearance and persistence of CD52-ne...

Aboutorabi R Ebrahimi B Esmaeili V Seyfali R, Shahverdi AH Sharbatoghli M

Background: Fertilization and fecundation obviously are the phenomenon in which several factors are involved. Sperm membranous proteins are a series of these important elements. CD9, an inner acrosomal membrane protein, is one of the tetraspanin members that involved in sperm-egg fusion. CD52, is a GPI anchor protein which is expressed in the epididymal cells and during passage of sperms throug...

2017
Guru P. Maiti Neil E. Kay Asish K. Ghosh

Tumor-secreted extracellular vesicles (EVs) including microvesicles (MVs) and exosomes, classified according to their sub-cellular origin [1], are critical mediators of intercellular communication between malignant cells and cells in local and distant microenvironments supporting metastatic niche formation. Clinically, EVs may be biomarkers and novel therapeutic targets that reflect cancer prog...

2017
Stephanie von Kutzleben Gareth Pryce Gavin Giovannoni David Baker

The objective was to determine whether CD52 lymphocyte depletion can act to promote immunological tolerance induction by way of intravenous antigen administration such that it could be used to either improve efficiency of multiple sclerosis (MS) inhibition or inhibit secondary autoimmunities that may occur following alemtuzumab use in MS. Relapsing experimental autoimmune encephalomyelitis was ...

2007
Jan J. Meeuse Herman G. Sprenger Sander van Assen Dominique Leduc Simon M.G.J. Daenen Jan P. Arends Tjip S. van der Werf

Rhodococcus equi, mainly known from veterinary medicine as a pathogen in domestic animals, can also cause infections in immunocompromised humans, especially in those with defects in cellular immunity. Alemtuzumab, an anti-CD52 monoclonal antibody, causes lymphocytopenia by eliminating CD52-positive cells. We report a patient in whom Rhodococcus equi infection developed after alemtuzumab therapy.

Journal: :Journal of Biological Chemistry 1995

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید